StayCurrentMD · Oncologic Outcomes of Parenchyma-Sparing Resection for Hepatoblastoma
Follow
Article1 min read·Published May 2026

Oncologic Outcomes of Parenchyma-Sparing Resection for Hepatoblastoma

jpedsurg.org shows its articles on its own site.

Read the article on jpedsurg.org ↗

Article · May 2026 · 1 min read

In brief

In brief

This study compares parenchyma-sparing resection (PSR) to standard resection techniques for hepatoblastoma, examining whether tissue-conserving approaches can achieve comparable oncologic outcomes. The research addresses an evolving surgical paradigm in pediatric liver tumor management.

  • Surgery remains the primary curative treatment for hepatoblastoma in pediatric patients.
  • Parenchyma-sparing resection is gaining acceptance as an alternative to traditional hemi-hepatectomy or trisectionectomy.
  • PSR aims to preserve functional liver tissue while achieving oncologic control in hepatoblastoma cases.
  • Comparative outcomes data between PSR and standard resection approaches are needed to guide surgical decision-making.

Written by the GCMD Library team from the article.

Surgery is the cornerstone of therapy for hepatoblastoma (HB). While standard resection (SR) via hemi-hepatectomy and trisectionectomy has traditionally been the preferred surgical approach, parenchyma-sparing resection (PSR) has become increasingly popular. We sought to compare the characteristics and outcomes of patients who underwent PSR versus SR.

Read it at the source ↗

Try
Intelligent Search· scoped to this article · not medical adviceSearch the whole library →